CD19CAR T cells demonstrate remarkable therapeutic efficacy in the treatment of B cell malignancies. A global limitation of conventional CD19CAR therapy is its mono-specificity. Thus, defining complementary targets to CD19 is critical to avoid target-dependent limitations. Alternatives to protein antigens include secon...
C. Forcados, H. Köksal, Eveline Scherer et al.· Cell Reports Medicine· 0 citations
Ovarian cancer (OC) is typically associated with poor prognosis and high mortality. Chimeric antigen receptor (CAR) T-cell therapy offers a promising strategy, yet its application in solid tumours remains constrained by limited efficacy and on-target/off-tumour toxicities. We previously developed K101CAR T cells target...
Alicia Villatoro, Aurore Dougé, K. Krpina et al.· The FEBS Journal· 0 citations
The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interacti...
Piyush Gondaliya, Dylan A. Zinn, A. A. Sayyed et al.· Molecular Pharmaceutics· 0 citations
It is shown that CAR structure is a critical determinant of CD19 loss in tumor B cells, and Mathematical modeling indicates that the failure of CD19-4-1BB-based CAR-T cells to eliminate CD19low cells, unlike CD28-based CARs, promotes the expansion of resistant populations.
Marta Krawczyk, K. Fidyt, Narcís Fernandez-Fuentes et al.· Leukemia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
